Polyclonal Antibody to WW Domain Containing E3 Ubiquitin Protein Ligase 2 (WWP2)
| Code | Size | Price |
|---|
| PAL087Hu01-20ul | 20ul | £93.00 |
Quantity:
| PAL087Hu01-100ul | 100ul | £175.00 |
Quantity:
| PAL087Hu01-200ul | 200ul | £237.00 |
Quantity:
| PAL087Hu01-1ml | 1ml | £547.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AIP2; WWp2-like; Atrophin-1-interacting protein 2; NEDD4-like E3 ubiquitin-protein ligase WWP2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
WW Domain Containing E3 Ubiquitin Protein Ligase 2
Reactivity:
Mu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:100-400<br/>Immunohistochemistry: 5-20ug/mL;1:10-40<br/>Immunocytochemistry: 5-20ug/mL;1:10-40<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant WW Domain Containing E3 Ubiquitin Protein Ligase 2 (WWP2) | RPL087Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||